别嘌醇与美国 2 型糖尿病退伍军人糖尿病性黄斑水肿风险。
Allopurinol and the Risk of Diabetic Macular Edema among U.S. Veterans with Type 2 Diabetes.
机构信息
Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina & Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
Dorn Research Institute, Columbia VA Health Care System, Columbia, South Carolina & Department of Epidemiology & Biostatistics, University of South Carolina, Columbia, South Carolina, USA.
出版信息
Ocul Immunol Inflamm. 2024 Aug;32(6):969-975. doi: 10.1080/09273948.2023.2170886. Epub 2023 Feb 7.
BACKGROUND
By inhibiting xanthine oxidase, subsequent inflammatory cytokine release and the resulting breakdown of the blood-retina barrier, allopurinol may limit the inflammation-driving diabetic macular edema (DME).
METHODS
We examined the relationship between allopurinol and DME among type 2 diabetic United States veterans using a retrospective cohort study. We used propensity score matching and Cox hazard models to estimate the risk of DME.
RESULTS
Propensity score-matched Cox models revealed allopurinol was associated with a 24.6% reduction in the risk of DME (HR = 0.754; 95% CI = (0.684-0.831)).
CONCLUSION
Allopurinol could reduce the risk of DME, one of the major causes of visual disturbance among diabetic patients. Further research into the effects of allopurinol on DME is warranted.
背景
通过抑制黄嘌呤氧化酶，随后减少炎症细胞因子的释放，并由此阻止血视网膜屏障的破坏，别嘌醇可能会限制炎症驱动的糖尿病性黄斑水肿（DME）。
方法
我们使用回顾性队列研究，在美国退伍军人的 2 型糖尿病患者中，研究了别嘌醇与 DME 之间的关系。我们使用倾向评分匹配和 Cox 风险模型来估计 DME 的风险。
结果
倾向评分匹配的 Cox 模型显示，别嘌醇可使 DME 的风险降低 24.6%（HR=0.754；95%CI=（0.684-0.831））。
结论
别嘌醇可降低 DME 的风险，DME 是糖尿病患者视力障碍的主要原因之一。有必要进一步研究别嘌醇对 DME 的影响。
Zotero 插件